Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioAtla, Inc. - Common Stock (NQ:BCAB)

0.4774 +0.0207 (+4.53%)
Streaming Delayed Price Updated: 1:43 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 208,189
Open 0.4611
Bid (Size) 0.4755 (11)
Ask (Size) 0.4798 (8)
Prev. Close 0.4567
Today's Range 0.4600 - 0.4973
52wk Range 0.2400 - 2.525
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Earnings Scheduled For May 6, 2025
Via Benzinga

Performance

YTD
-22.2%
-22.2%
1 Month
+0.4%
+0.4%
3 Month
+45.1%
+45.1%
6 Month
-69.4%
-69.4%
1 Year
-72.6%
-72.6%

More News

Read More
A Preview Of BioAtla's Earnings
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Earnings Outlook For BioAtla
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
BCAB Stock Earnings: BioAtla Meets EPS for Q2 2024
Via InvestorPlace
BCAB Stock Earnings: BioAtla Beats EPS for Q1 2024
Via InvestorPlace
Earnings Scheduled For March 27, 2025
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
BCAB Stock Earnings: BioAtla Beats EPS for Q4 2023
Via InvestorPlace
BioAtla: Q4 Earnings Insights
Via Benzinga
Preview: BioAtla's Earnings
Via Benzinga
'Big Short' Investor Michael Burry's China Bet Pays Off As Top Picks Surge Nearly 60% In 2 Months
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
From Context Therapeutics Inc.
Via GlobeNewswire
'Big Short' Fame Michael Burry Bets Big On China, Reveals Alibaba As Top Holding — JD.com And Baidu Also Feature On Scion's Portfolio
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Around $2M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
Topics Stocks
Exposures US Equities
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From BioAtla, Inc.
Via GlobeNewswire
Earnings Scheduled For March 26, 2024
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
From BioAtla, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga

Frequently Asked Questions

Is BioAtla, Inc. - Common Stock publicly traded?
Yes, BioAtla, Inc. - Common Stock is publicly traded.
What exchange does BioAtla, Inc. - Common Stock trade on?
BioAtla, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BioAtla, Inc. - Common Stock?
The ticker symbol for BioAtla, Inc. - Common Stock is BCAB on the Nasdaq Stock Market
What is the current price of BioAtla, Inc. - Common Stock?
The current price of BioAtla, Inc. - Common Stock is 0.4774
When was BioAtla, Inc. - Common Stock last traded?
The last trade of BioAtla, Inc. - Common Stock was at 06/06/25 01:43 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.